19:49 , Apr 20, 2018 |  BC Week In Review  |  Clinical News

Symic's SB-061 misses in Phase II for OA of the knee

In February, Symic Bio Inc. (Emeryville, Calif.) reported top-line data from the Phase II MODIFY2 trial in 60 patients with mild to moderate osteoarthritis (OA) of the knee showing that a single intra-articular injection of...
19:23 , May 23, 2017 |  BC Extra  |  Financial News

Symic Bio raises $30M in series B

Matrix biology company Symic Bio Inc. (Emeryville, Calif.) raised $30 million in a series B round from new investor HEDA Ventures and existing investors Lilly Ventures, Den Danske Forskningsfond, Ally Bridge Group, InCube Ventures and...
14:32 , Nov 17, 2016 |  BC Week In Review  |  Clinical News

SB-061: Completed Ph I/IIa enrollment

Symic and Nordic completed enrollment of 147 patients in the double-blind, placebo-controlled, European Phase I/IIa MODIFY-OA trial evaluating 2 intra-articular injections of SB-061. Last year, Symic and Nordic partnered to develop Symic's SB-061. Nordic Bioscience...
07:00 , Aug 15, 2016 |  BioCentury  |  Finance

Serving returns

China's Ally Bridge Group hit the investment world's radar in 2015 with its audacious move to take CRO WuXi PharmaTech Inc. private. If the firm and its partners can engineer the first fruits of that...
07:00 , Jul 11, 2016 |  BC Week In Review  |  Clinical News

SB061: Phase I/II started

Symic and Nordic Bioscience began the double-blind, placebo-controlled, Estonian Phase I/II MODIFY-OA trial to evaluate intra-articular injections of SB061 in about 90 patients. In 2015, Symic and Nordic partnered to develop SB061. Nordic Bioscience A/S...
07:00 , Apr 7, 2016 |  BC Innovations  |  Product R&D

Branching out

With its second compound about to hit the clinic and a fresh influx of money, Symic Biomedical Inc. is lining up the next three preclinical programs for its extracellular matrix (ECM)-targeting technology. By applying each...
01:46 , Dec 2, 2015 |  BC Extra  |  Financial News

Symic raises $25M in series A-2 round

Symic Biomedical Inc. (San Francisco, Calif.) raised $25 million in a series A-2 round led by existing investor Lilly Ventures. New investors Alexandria Real Estate and Purdue Research Foundation also participated, as did existing investors...
08:00 , Jan 5, 2015 |  BioCentury  |  Emerging Company Profile

Mimicking proteoglycans

Symic Biomedical Inc. is developing a library of synthetic mimics that function like natural proteoglycans but are easier to manufacture and aren't susceptible to enzymatic degradation, opening up previously untapped therapeutic space. Proteoglycans, which are...
08:00 , Dec 11, 2014 |  BC Innovations  |  Targets & Mechanisms

PIEZO de resistance

A pair of recently identified calcium channels- PIEZO1 and PIEZO2-control the response of cartilage to heavy loads and offer new targets for joint injury and osteoarthritis, according to findings from a team at Duke University...
07:00 , Sep 19, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Pain Hyaluronan and proteoglycan link protein 1 (HAPLN1; LPP) In vitro studies suggest LPP could help treat intervertebral disc degeneration-associated chronic lower back pain. Treatment...